Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:07 AM
Ignite Modification Date:
2025-12-26 @ 11:07 AM
NCT ID:
NCT03574012
Eligibility Criteria:
Inclusion Criteria:
* Prior diagnosis of an acute leukemia or lymphoma or any receipt of HCT for a malignant condition.
* At time of approach, \>= 5 years from initial cancer diagnosis or \>= 5 years from first HCT, whichever is later.
* Currently in remission and not on any active anti-cancer therapies (survivors receiving maintenance tyrosine kinase inhibitors are NOT eligible).
* Able to read, write, and speak English.
* Access to smart phone or computer with internet access.
* Presence of at least 1 CV risk factor:
* Currently on medication for hypertension, or
* Currently on medication for cholesterol or triglyceride, or
* Currently on medication for diabetes, or
* Currently not physically active (self-reported average \< 30 minutes/day), or
* Currently smoking.
* Ability to understand and the willingness to provide informed consent.
Exclusion Criteria:
* Pre-existing ischemic heart disease (includes angina if documented in electronic medical record \[EMR\]) or ongoing symptomatic cardiomyopathy (those with asymptomatic cardiomyopathy may be allowed to participate if they do not have any current activity restrictions, but we will seek physician clearance for any submaximal exercise testing).
* Active systemic treatment for graft versus host disease.
* Currently pregnant. However, participants enrolled who become pregnant after randomization can remain on the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
55 Years
Study:
NCT03574012
Study Brief:
Protocol Section:
NCT03574012